Differentiation between the oka varicella vaccine virus and American wild-type varicella-zoster virus (VZV).
Differentiation between the oka varicella vaccine virus and American wild-type varicella-zoster virus (VZV).
复制标题
冈水痘疫苗病毒和美国野生型水痘带状疱疹病毒 (VZV) 之间的区别。
DOI：
10.1007/978-1-4684-5853-4_7
复制
发表时间：
1990
影响因子：
--
通讯作者：
Dohner,DE
中科院分区：
文献类型：
--
作者：
Gelb,LD;Adams,SG;Dohner,DE
Takahashi和他的同事在20世纪70年代早期研制出水痘-带状疱疹减毒活疫苗（VZV）。该疫苗被命名为奥卡菌株，以从该儿童身上分离出病毒。衰减被认为是由原始临床分离物在不同温度和不同细胞系中连续传代引起的（1,2）。随后，世界各地的大量研究表明，该疫苗对健康和免疫抑制个体都是安全的、具有免疫原性的和高度保护性的（3-6）。
A live attenuated varicella-zoster virus (VZV) vaccine was developed by Takahashi and his colleagues in the early 1970s (1). The vaccine has been designated the Oka strain after the child from whom the virus was isolated. Attenuation was believed to have been induced by serial passage of the original clinical isolate at various temperatures and in different cell lines (1, 2). Numerous studies throughout the world have subsequently shown the vaccine to be safe, immunogenic, and highly protective in both healthy and immunosuppressed individuals (3–6).